The acquisition adds first-in-class BK polyomavirus candidate potravitug as Ipsen continues an aggressive week of dealmaking following its Kartos Therapeutics takeover.

Late-stage myelofibrosis candidate navtemadlin could reshape treatment for patients with suboptimal responses to Jakafi.